McClellan Sees Roadblocks To Passing Biogenerics Bill This Year
Executive Summary
Former FDA and CMS chief Mark McClellan sees a number of potential roadblocks to passing generic biologics legislation in 2007
You may also be interested in...
PDUFA Draft Bill Adds $70 Mil. For Rx Safety To User Fee Totals; Mark-Up Looms
A draft of the bill to reauthorize FDA's user fee program would add $70 million to the total fee negotiated by the agency and industry in order to pay for additional Rx safety oversight
PDUFA Draft Bill Adds $70 Mil. For Rx Safety To User Fee Totals; Mark-Up Looms
A draft of the bill to reauthorize FDA's user fee program would add $70 million to the total fee negotiated by the agency and industry in order to pay for additional Rx safety oversight
Scientific, Not Legal, Developments Are Key To Generic Biologics – McClellan
Generic drug firms can speed creation of a pathway for generic biologics by focusing on the science behind the products, former FDA commissioner Mark McClellan said